ALK and non-small cell lung carcinoma: Atezolizumab plus carboplatin plus paclitaxel plus bevacizumab (ACPB) regimen significantly improved the PFS and OS in advanced NSCLC patients, regardless of PD‐L1 expression and EGFR or ALK genetic alteration status.308